These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36014415)

  • 1. In Silico and In Vitro Studies of
    Suručić R; Radović Selgrad J; Kundaković-Vasović T; Lazović B; Travar M; Suručić L; Škrbić R
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alchemilla viridiflora Rothm.: the potent natural inhibitor of angiotensin I-converting enzyme.
    Radović J; Suručić R; Niketić M; Kundaković-Vasović T
    Mol Cell Biochem; 2022 Jul; 477(7):1893-1903. PubMed ID: 35348979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
    Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
    Zaheer M; Ali N; Javed H; Munir R; Jamil N
    J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
    Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
    Qiao B; Olvera de la Cruz M
    ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomegranate peel extract polyphenols attenuate the SARS-CoV-2 S-glycoprotein binding ability to ACE2 Receptor: In silico and in vitro studies.
    Suručić R; Travar M; Petković M; Tubić B; Stojiljković MP; Grabež M; Šavikin K; Zdunić G; Škrbić R
    Bioorg Chem; 2021 Sep; 114():105145. PubMed ID: 34246969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
    Verkhivker G
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
    Basu A; Sarkar A; Maulik U
    Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
    Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
    ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
    Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
    Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
    Li C; Zhou H; Guo L; Xie D; He H; Zhang H; Liu Y; Peng L; Zheng L; Lu W; Mei Y; Liu Z; Huang J; Wang M; Shu D; Ding L; Lang Y; Luo F; Wang J; Huang B; Huang P; Gao S; Chen J; Qian CN
    J Transl Med; 2022 Jul; 20(1):314. PubMed ID: 35836239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
    Guo X; Chen Z; Xia Y; Lin W; Li H
    J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
    Cantuti-Castelvetri L; Ojha R; Pedro LD; Djannatian M; Franz J; Kuivanen S; van der Meer F; Kallio K; Kaya T; Anastasina M; Smura T; Levanov L; Szirovicza L; Tobi A; Kallio-Kokko H; Österlund P; Joensuu M; Meunier FA; Butcher SJ; Winkler MS; Mollenhauer B; Helenius A; Gokce O; Teesalu T; Hepojoki J; Vapalahti O; Stadelmann C; Balistreri G; Simons M
    Science; 2020 Nov; 370(6518):856-860. PubMed ID: 33082293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.